Latest Deals
Credit: SewCreamStudio / Shutterstock
Baxter signs over kidney care arm to investment firm in $3.5bn deal
US medtech giant Baxter has announced today (13 August) the signing of a definitive agreement divesting itself of the kidney care segment, handing the business over to global investment company Carlyle in a $3.5bn deal. The agreement comes following a March 2024 announcement in which the company detailed that it was looking to either spin out or sell off its kidney care wing, set to be renamed Vantive, in hopes of improving its overall performance as well as paying off debts.
Mallinckrodt sells Therakos to CVC Capital Partners for $925m
Speciality pharmaceutical company Mallinckrodt is selling its Therakos business to CVC Capital Partners for $925m. Mallinckrodt, a manufacturer of branded and generic drugs, purchased Therakos back in 2015 for $1.33bn. Mallinckrodt said that it will use the proceeds from the latest deal to reduce net debt by more than 50%.
Sable Therapeutics and Columbia sign deal on obesity treatments
Sable Therapeutics has entered into an exclusive global licensing agreement with Columbia University to develop new polycation nanomedicines aimed at treating obesity. The partnership will focus on progressing a portfolio of compounds, SBL-001 and SBL-002, targeting both visceral and subcutaneous adiposity. SBL-001 and SBL-002 are designed to significantly diminish fat cell volume and have been uniquely engineered for selective uptake by adipose cells.
MSD sets sights on bispecific antibody market with Curon acqusition
Merck & Co (MSD) has announced that it is set to acquire B cell-targeting therapy, CN201, from Curon Biopharmaceutical. MSD will purchase the clinical stage candidate through a subsidiary with an upfront cash payment of $700m. Curon is eligible to receive up to $600m for developmental and regulatory milestones. MSD expects to complete the deal in Q3 2024.
